Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.79
+0.05 (0.27%)
At close: May 1, 2026, 4:00 PM EDT
16.74
-0.05 (-0.27%)
After-hours: May 1, 2026, 4:24 PM EDT
Theravance Biopharma Revenue
In the year 2025, Theravance Biopharma had annual revenue of $107.46M with 66.92% growth. Theravance Biopharma had revenue of $45.89M in the quarter ending December 31, 2025, with 144.70% growth.
Revenue (ttm)
$107.46M
Revenue Growth
+66.92%
P/S Ratio
8.05
Revenue / Employee
$1,194,044
Employees
90
Market Cap
864.31M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 107.46M | 43.08M | 66.92% |
| Dec 31, 2024 | 64.38M | 6.96M | 12.12% |
| Dec 31, 2023 | 57.42M | 6.08M | 11.84% |
| Dec 31, 2022 | 51.35M | -3.97M | -7.17% |
| Dec 31, 2021 | 55.31M | -16.55M | -23.03% |
| Dec 31, 2020 | 71.86M | -1.56M | -2.12% |
| Dec 31, 2019 | 73.41M | 13.04M | 21.61% |
| Dec 31, 2018 | 60.37M | 44.98M | 292.37% |
| Dec 31, 2017 | 15.39M | -33.26M | -68.37% |
| Dec 31, 2016 | 48.65M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Phathom Pharmaceuticals | 175.11M |
| Xencor | 125.58M |
| MeiraGTx Holdings | 81.39M |
| CytomX Therapeutics | 76.20M |
| Janux Therapeutics | 10.00M |
TBPH News
- 4 weeks ago - TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 6 weeks ago - Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Theravance Biopharma Plummets As Phase 3 Study Falls Short - Benzinga
- 2 months ago - Theravance plans strategic review, including possible sale, after drug trial failure - Reuters
- 2 months ago - Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions - PRNewsWire
- 5 months ago - Theravance Biopharma Transcript: KOL Event - Transcripts
- 5 months ago - Theravance Biopharma Transcript: Evercore ISI 8th Annual HealthCONx Conference - Transcripts
- 5 months ago - Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - PRNewsWire